United States Atherectomy Devices Market to Reach US$ 627.59 Million by 2033 as Minimally Invasive Cardiovascular Treatments Gain Momentum

United States Atherectomy Devices Market Size and Forecast 2025–2033

The United States Atherectomy Devices Market is witnessing significant growth as healthcare providers increasingly adopt minimally invasive solutions for the treatment of cardiovascular diseases. According to Renub Research, the market is projected to expand from US$ 316.05 Million in 2024 to US$ 627.59 Million by 2033, registering a strong CAGR of 7.92% during 2025–2033.

Download Free Sample Report:

The growth trajectory reflects the rising burden of cardiovascular disorders, increased diagnosis of peripheral artery disease (PAD), advancements in atherectomy technologies, and growing patient preference for procedures that reduce hospital stays and recovery periods. As cardiovascular diseases continue to remain among the leading causes of mortality in the United States, the demand for innovative plaque-removal technologies is expected to increase steadily over the coming decade.

Understanding Atherectomy Devices and Their Clinical Importance

Atherectomy devices are specialized medical tools used to remove atherosclerotic plaque from blood vessels. Unlike traditional angioplasty, which compresses plaque against arterial walls, atherectomy physically removes or vaporizes the blockage, helping restore blood flow more effectively in selected patients.

These devices play an important role in treating conditions such as:

Peripheral Artery Disease (PAD)

Coronary Artery Disease (CAD)

Critical Limb Ischemia

Calcified Arterial Lesions

In-Stent Restenosis

Modern atherectomy procedures are frequently performed alongside balloon angioplasty and stent placement, creating comprehensive treatment strategies that improve long-term vascular outcomes.

The U.S. healthcare system has increasingly embraced these technologies because they offer less invasive alternatives to open surgery while improving patient comfort and reducing hospitalization time.

Rising Cardiovascular Disease Burden Driving Market Expansion

One of the strongest drivers behind the atherectomy devices market is the growing incidence of cardiovascular disorders across the United States.

Millions of Americans suffer from arterial blockages caused by atherosclerosis, a condition characterized by plaque buildup within blood vessels. Factors contributing to this trend include:

Aging population

Obesity

Diabetes

Sedentary lifestyles

Smoking

Hypertension

Peripheral Artery Disease alone affects more than 12 million Americans, and many cases remain undiagnosed until symptoms become severe.

As healthcare providers encounter larger patient populations requiring vascular interventions, atherectomy procedures are becoming an increasingly valuable treatment option. The ability to remove heavily calcified plaque while preserving healthy arterial tissue makes these devices especially attractive for complex cases.

The rising prevalence of chronic diseases ensures a sustained demand pipeline for atherectomy technologies throughout the forecast period.

Technological Innovation Continues to Transform the Industry

The U.S. atherectomy market is heavily influenced by continuous innovation from leading medical device manufacturers.

Recent product developments have introduced:

Improved plaque removal efficiency

Enhanced catheter flexibility

Better lesion-crossing capabilities

Real-time imaging integration

Reduced procedural complications

Greater physician control

Advanced systems now combine atherectomy with intravascular imaging technologies, enabling physicians to visualize lesions with unprecedented accuracy before, during, and after treatment.

Laser, orbital, rotational, and directional atherectomy platforms continue to evolve, offering physicians multiple options based on lesion characteristics and patient requirements.

These advancements have improved procedural outcomes while increasing physician confidence in adopting atherectomy-based interventions.

Expanding Reimbursement Support Encourages Adoption

Reimbursement remains a critical factor influencing medical device adoption in the United States.

Fortunately for the atherectomy market, both Medicare and private insurers increasingly recognize the clinical value of minimally invasive vascular interventions.

Improved reimbursement policies provide several benefits:

Increased patient access

Better affordability

Higher hospital adoption rates

Greater physician utilization

Improved return on investment for healthcare facilities

Since PAD primarily affects older adults, Medicare coverage plays a particularly important role in supporting procedural growth.

As reimbursement frameworks continue evolving toward value-based care models, atherectomy devices are expected to benefit from stronger integration into cardiovascular treatment pathways.

Key Challenges Facing the Market

High Cost of Devices and Procedures

Despite promising growth prospects, atherectomy procedures remain expensive.

Hospitals must invest heavily in:

Capital equipment

Disposable catheters

Training programs

Maintenance costs

While insurance often covers portions of the treatment, patient out-of-pocket expenses can still be substantial.

Smaller healthcare facilities and rural hospitals frequently face budgetary limitations that restrict access to advanced atherectomy technologies.

Cost pressures remain one of the primary obstacles preventing broader market penetration.

Shortage of Skilled Specialists

Atherectomy procedures require extensive expertise and training.

Potential complications include:

Distal embolization

Arterial perforation

Vessel dissection

Restenosis

As a result, only highly trained interventional cardiologists and vascular specialists perform these procedures regularly.

Many rural and underserved regions continue to experience shortages of qualified specialists, limiting patient access and slowing adoption rates outside major metropolitan healthcare centers.

Directional Atherectomy Segment Maintains Strong Growth

Directional atherectomy devices have become increasingly popular due to their ability to selectively remove plaque while preserving healthy vessel tissue.

Advantages include:

High precision

Effective treatment of eccentric lesions

Better plaque targeting

Reduced vessel trauma

Modern directional systems incorporate sophisticated imaging capabilities that help physicians navigate complex arterial anatomy.

Growing preference among cardiovascular specialists is expected to support sustained growth in this segment throughout the forecast period.

Laser Atherectomy Emerges as a High-Growth Segment

Laser atherectomy has gained substantial traction due to its unique ability to vaporize plaque using concentrated light energy.

Clinical advantages include:

Minimal mechanical vessel trauma

Effective treatment of in-stent restenosis

Superior precision

Reduced procedural complications

Healthcare providers increasingly utilize laser systems for both coronary and peripheral interventions.

As technological improvements continue to enhance safety and efficiency, laser atherectomy is expected to capture a growing share of the U.S. market.

Cardiovascular Applications Lead Overall Demand

Cardiovascular disease remains the leading cause of death in the United States, creating strong demand for advanced treatment technologies.

Atherectomy devices are increasingly used alongside:

Balloon angioplasty

Drug-coated balloons

Vascular stents

This integrated treatment approach helps optimize blood flow restoration while improving long-term patient outcomes.

The expanding evidence base supporting atherectomy efficacy continues to drive physician adoption across cardiovascular specialties.

Hospitals Remain the Largest End-User Segment

Hospitals account for the majority of atherectomy procedures performed in the United States.

Several factors support hospital dominance:

Access to specialized physicians

Advanced imaging infrastructure

Ability to manage complex cases

Comprehensive reimbursement systems

Participation in clinical research programs

Large healthcare systems often maintain multiple atherectomy platforms, enabling personalized treatment approaches for diverse patient populations.

As cardiovascular intervention volumes increase nationwide, hospitals will remain the primary growth engine for the market.

Regional Market Insights

California

California represents one of the largest atherectomy device markets in the country.

The state's strong position is supported by:

Large patient population

Advanced healthcare infrastructure

Presence of leading medical device innovators

Significant cardiovascular disease burden

Additionally, California's prominent research institutions frequently participate in clinical trials evaluating next-generation vascular technologies.

New York

New York continues to be a major market due to:

High population density

Advanced hospital networks

Strong physician expertise

High rates of diabetes and PAD

Major academic medical centers in New York often serve as referral hubs for complex cardiovascular interventions.

New Jersey

New Jersey is emerging as a promising growth market.

The state's aging population, expanding cardiovascular care infrastructure, and proximity to leading healthcare hubs contribute to rising atherectomy adoption rates.

Hospitals and outpatient centers throughout New Jersey are increasingly integrating advanced vascular technologies into treatment protocols.

10 Recent Developments from Leading Atherectomy Device Companies

1. Boston Scientific Corporation

Expanded its peripheral intervention portfolio through ongoing enhancements to advanced atherectomy and vascular treatment technologies aimed at improving outcomes for PAD patients.

2. Abbott Laboratories

Continued investments in vascular imaging and interventional cardiology technologies that complement atherectomy procedures and improve lesion assessment.

3. Medtronic plc

Strengthened its cardiovascular innovation pipeline through next-generation vascular intervention solutions focused on complex arterial disease management.

4. Cardinal Health

Enhanced distribution capabilities for cardiovascular devices, helping improve nationwide access to advanced interventional technologies.

5. Terumo Corporation

Expanded global vascular solutions offerings and increased investments in minimally invasive cardiovascular treatment technologies.

6. Integer Holdings Corporation

Increased manufacturing support for next-generation catheter-based technologies used across interventional cardiology and atherectomy procedures.

7. Becton, Dickinson and Company (BD)

Advanced its peripheral intervention portfolio through innovation initiatives focused on improving physician workflow and patient outcomes.

8. AngioDynamics Inc.

Continued expanding minimally invasive vascular treatment solutions and strengthening clinical evidence supporting peripheral artery disease interventions.

9. Royal Philips

Initiated enrollment in the U.S. THOR IDE trial evaluating a combined laser atherectomy and intravascular lithotripsy catheter for treating peripheral artery disease, marking a significant advancement in vascular intervention technology.

10. Healthcare Providers and Research Institutions

Multiple U.S. hospital systems and research organizations launched clinical studies evaluating newer atherectomy techniques, imaging integration, and plaque modification technologies to improve long-term procedural success.

Competitive Landscape

The United States Atherectomy Devices Market remains highly competitive, with leading manufacturers focusing on innovation, strategic partnerships, clinical evidence generation, and physician education programs.

Major companies operating in the market include:

Boston Scientific Corporation

Abbott Laboratories

Medtronic plc

Cardinal Health

Terumo Corporation

Integer Holdings Corporation

Becton, Dickinson and Company

AngioDynamics Inc.

These organizations continue investing heavily in research and development to strengthen their positions in the rapidly expanding cardiovascular intervention market.

Final Thoughts

The United States Atherectomy Devices Market is entering a period of sustained expansion driven by rising cardiovascular disease prevalence, growing awareness of peripheral artery disease, and continuous advancements in minimally invasive treatment technologies.

With the market forecast to grow from US$ 316.05 Million in 2024 to US$ 627.59 Million by 2033, the sector is poised for remarkable progress. Innovations in directional, rotational, orbital, and laser atherectomy systems are helping physicians deliver safer and more effective treatments while improving patient quality of life.

Although challenges such as procedural costs and specialist shortages remain, favorable reimbursement policies, technological breakthroughs, and increasing clinical adoption are expected to keep the market on a strong upward trajectory through 2033.